BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210622T190000
DTEND;TZID=Africa/Nairobi:20210622T203000
DTSTAMP:20211024T153712Z
CREATED:20210530T154745Z
LAST-MODIFIED:20211024T153712Z
UID:5215-1624388400-1624393800@kesho-kenya.org
SUMMARY:Cytoreductive Surgery (CRS) And Hyperthermic Intraperitoneal Perfusion (HIPEC)
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Mohammed Ezzi \nSponsor: RAND \nPresenters: \n\nProf Ignace De Hingh\, MD\, PhD\, Catharina Cancer Institute\, Eindhoven\, The Netherlands\nUmberto Carletti\, Clinical perfusionist\, Product Manager\,  RAND\nDr. Abdi Hakin Mohammed\, Surgical Oncologist\, and Consultant Laparoscopic Surgeon\, Mombasa.\n\nPeritoneal metastases (PM) affect hundreds of thousands of patients a year globally. The patients have a very poor prognosis\, without adequate treatment. PM is not a systemic but a regional disease\, initially regarded as untreatable\, resistant to systemic chemotherapy\, and refractory to surgery. Accumulating evidence suggests that PM can be treated by radical regional combination therapy. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal perfusion (HIPEC) is associated with significantly improved recurrence-free and overall survival in ovarian and Pseudomyxoma peritonei (PMP low-grade rare clinical condition) patients\, without increasing toxicity. CRS-HIPEC program can be safely implemented in high-volume dedicated centers\, though currently\, there is an unmet need for this technology since there is no center in Kenya offering the services.  Rand Company in Italy is producing systems for HIPEC\, which ideally should be effective\, easy to use with automatic functions\, traceable\, safe\, controlled\, and supported by clinical experts. The cost of installing the machine is on average 3.4-4 million Kenya shillings and is cost-effective since each procedure requires one kit. The machine is easy to use and any nurse can use the machine without perfusion skills. The company offers training to individuals using the machine in their respective countries.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-perfusion-hipec/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/05/cytoreductive.jpg
END:VEVENT
END:VCALENDAR